172 related articles for article (PubMed ID: 21460180)
21. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
23. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression.
Benito R; Lumbreras E; Abáigar M; Gutiérrez NC; Delgado M; Robledo C; García JL; Rodríguez-Vicente AE; Cañizo MC; Rivas JM
Pharmacogenet Genomics; 2012 May; 22(5):381-8. PubMed ID: 22388797
[TBL] [Abstract][Full Text] [Related]
24. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
25. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Tipping AJ; Deininger MW; Goldman JM; Melo JV
Exp Hematol; 2003 Nov; 31(11):1073-80. PubMed ID: 14585372
[TBL] [Abstract][Full Text] [Related]
26. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
27. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
[TBL] [Abstract][Full Text] [Related]
28. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
31. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
Liu L; Wang S; Chen R; Wu Y; Zhang B; Huang S; Zhang J; Xiao F; Wang M; Liang Y
Biochem Biophys Res Commun; 2012 Aug; 425(2):368-73. PubMed ID: 22842456
[TBL] [Abstract][Full Text] [Related]
32. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
34. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.
Richebourg S; Eclache V; Perot C; Portnoi MF; Van den Akker J; Terré C; Maareck O; Soenen V; Viguié F; Laï JL; Andrieux J; Corm S; Roche-Lestienne C;
Cancer Genet Cytogenet; 2008 Apr; 182(2):95-102. PubMed ID: 18406870
[TBL] [Abstract][Full Text] [Related]
36. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
[TBL] [Abstract][Full Text] [Related]
37. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Li Y; Yang L; Pan Y; Yang J; Shang Y; Luo J
Oncol Rep; 2014 May; 31(5):2438-46. PubMed ID: 24647617
[TBL] [Abstract][Full Text] [Related]
38. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Campbell LJ; Fidler C; Eagleton H; Peniket A; Kusec R; Gal S; Littlewood TJ; Wainscoat JS; Boultwood J
Leukemia; 2006 Apr; 20(4):671-9. PubMed ID: 16498395
[TBL] [Abstract][Full Text] [Related]
39. Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients.
Estrada-González PK; Gómez-Ceja L; Montesinos JJ; Mayani H; Chávez-González A; Meillón L; Delgado N; Sánchez-Nava E; Flores-Figueroa E
Leuk Res; 2014 May; 38(5):594-600. PubMed ID: 24661629
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
Soltani I; Douzi K; Gharbi H; Benhassine I; Teber M; Amouri H; Ben Hadj Othman H; Farrah A; Ben Lakhel R; Abbes S; Menif S
Hematology; 2017 May; 22(4):201-207. PubMed ID: 27825294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
